HEALTHCARE · NSE/BSE: DRAGARWQ

Dr Agarwals Eye Hospital Limited Earnings Summary — Q1 FY2027

Sentiment: Positive
AI-generated summary
Generated 2026-08-04
Generated using: Official Earnings Press Release
Business Intelligence Report

Dr. Agarwal's Eye Hospital Reports Strong Q1 Growth as Amalgamation with Parent Company Progresses

Quarterly Business Intelligence

Q1 FY2027
Financials from Financial Intelligence · data as of 2026-06-30
Revenue
₹143 Cr
QoQ +19.1%YoY +22.3%
Net Profit
₹23 Cr
QoQ +44.0%YoY +35.5%
Operating Profit
₹43 Cr
QoQ +28.3%YoY +16.5%
Operating Margin
30.3%
QoQ +215 bpsYoY -150 bps

AI Quarterly Scorecard™

77
/ 100
Strong
Revenue Momentum98
Profit Growth98
Margin Expansion60
Growth Consistency75
Operating Efficiency61
Financial Stability71

Computed deterministically from the last 10 reported quarters.

Quarterly Business Momentum

Revenue & Growth
  • Revenue has increased for 3 consecutive quarters.
  • Revenue of ₹143 Cr is 22.3% higher year-on-year.
  • Revenue has compounded at 28.9% annualised over the last 10 quarters.
  • Revenue is at its highest level in 10 quarters.
Profitability
  • Net profit has reached its highest level in 10 quarters.
  • Net profit of ₹23 Cr is 35.5% above the same quarter last year.
  • Profit growth is outpacing revenue growth, pointing to positive operating leverage.
  • Net profit has compounded at 30.7% annualised across the period.
Margins
  • Operating margin stands at 30.3% in Q1 FY2027.
  • Operating margin compressed by 150 bps year-on-year.
  • Over the last two years operating margin has contracted by 114 bps.
  • PBT margin is 21.6%.
Operating Efficiency
  • Expenses grew 25.0% against revenue growth of 22.3%.
  • Operating profit of ₹43 Cr is 16.5% higher year-on-year.
  • Operating leverage continues to improve.
Overall Momentum
  • 6 of the last 6 measured quarters delivered year-on-year revenue growth.
  • Overall quarterly business momentum scores 77/100 (Strong) on the latest 10 quarters.
  • Business momentum remains positive heading into the next quarter.

Quarterly Financials

Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %

MetricTrend
Latest
Q1 FY2027
Q4 FY2026Q3 FY2026Q2 FY2026Q1 FY2026Q4 FY2025Q3 FY2025Q2 FY2025Q1 FY2025Q4 FY2024
Revenue
Improving
143
1201161181171009510210081
Expenses
Improving
100
868278806869726956
Operating Profit
Improving
43
343440373226303124
Operating Margin
Stable
30.3%
28.1%29.6%34.0%31.8%31.6%26.9%29.2%31.4%30.3%
Other Income
Improving
2
231102202
Interest
Improving
3
224434432
Depreciation
Improving
11
1212111110109108
Profit Before Tax
Improving
31
212326231914191917
Tax
Volatile
8
566634555
Net Profit
Improving
23
161719171610141413
Net Margin
Stable
16.4%
13.5%14.9%16.4%14.8%16.0%10.9%13.8%14.1%15.8%
Source: Financial Intelligence (Structured Quarterly Data)Latest Quarter: Q1 FY2027Figures in ₹ Crore • Margins in %Automatically updated from Financial Intelligence · 2026-06-30

Key Takeaways

  • Revenue from operations grew 22.3% YoY to ₹142.97 crore, driven by expansion in surgical volumes.
  • Net Profit surged by 35.5% YoY to ₹23.38 crore, reflecting significant operational leverage.
  • EBITDA for the quarter stood at ₹45.22 crore, compared to ₹37.93 crore in the same period last year.
  • The Board approved the re-appointment of M/s. B Y & Associates as Cost Auditors for FY2026-27.
  • Shareholding data shows a steady increase in institutional confidence, with FII stake rising to 2.24%.
  • Company is in the process of a strategic merger with its parent entity, Dr. Agarwal’s Health Care Limited (AHCL).

Management Guidance

The merger with parent AHCL is intended to create a unified platform for growth, simplify the corporate structure, and enhance financing capacity for future geographic expansion.

Sentiment Shift

Improving

Profitability growth outpaced revenue growth, indicating better cost management and higher-value surgical mix.

Growth-oriented
Specialized
Expansionary

Outlook

The merger with AHCL, expected to conclude by Q2 FY2027, will consolidate the group's 230+ facilities, creating India's largest eye care chain with a unified capital allocation strategy.

From the Annual Report (Key Quotes)

The Board of Directors... has considered and approved the Unaudited Financial Results for the quarter ended June 30, 2026.

Creation of a unified platform for growth through the simplification of the Group Structure.

Merger expected to benefit shareholders across AHCL & AEHL; expected to be EPS accretive from first year of implementation.

Official Quarterly Documents

Earnings Press Release
Official quarterly earnings release published by the company.
Download
Earnings Call Transcript
Management discussion and analyst Q&A.

Ask AI about this quarter

Sign in to ask AI questions grounded on the official earnings release and call transcript.

This summary is AI-generated from Dr Agarwals Eye Hospital Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.

← Back to Dr Agarwals Eye Hospital Limited AI analysis